News – Page 820 – Endpoints News

Ultragenyx’s ultra-expensive ultra-rare disease drug earns second nod; Another round of promising NASH data

5 years ago

Prominent Harvard professor in the hunt for $100M to back his anti-aging play

5 years ago

Boehringer Ingelheim nabs new US president and CEO; AstraZeneca vet hops aboard Novavax as CMO

5 years ago

AbbVie sweeps out experimental gastro drugs in a post-merger pipeline cleanup. And they can likely be yours for the ...

5 years ago

The biotech IPOs keep coming at chart-topping levels — with no slowdown in sight

5 years ago

Covid-19 roundup: One Chinese biotech enters clinic, another eyes fall completion, a third shoots for 2021 — while ...

5 years ago

'A turning point for the field': 4 years after Seres failure, Finch posts positive microbiome data

5 years ago

Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma

5 years ago

Hours after blockbuster patent win, Mylan asks the FDA to speed up an OK to market a generic to Biogen’s Tecfidera

5 years ago

One of Roche’s spotlight PhIII cancer drug hopefuls stumbles in a key trial, with hit-and-miss results

5 years ago

AbbVie’s Rinvoq passes PhIII AD test; Dicerna races Alnylam; New Sarepta gene & cell collab

5 years ago

In a fresh blow, Biogen loses a big court fight with Mylan over its blockbuster Tecfidera patent

5 years ago

Nan Fung Life Sciences antes up $32M to fuel a neuro play as the Hong Kong conglomerate burns through $1.5B mandate

5 years ago

AbbVie-Allergan complete, but critics continue to raise anti-competitive concerns

5 years ago

As BioMarin’s lead rival wanes, Pfizer and Sangamo post a promising update for hemophilia A gene therapy

5 years ago

AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock ...

5 years ago

Tecentriq passes neoadjuvant breast cancer trial as Roche looks for early start on the next big checkpoint ...

5 years ago

FDA offers statistical guidance for trials impacted by Covid-19

5 years ago

Covid-19 roundup: Roche's Actemra marred by negative results; Here comes another single-armed remdesivir trial

5 years ago

Chinese vaccine developers have begun to shed some secrecy around Covid-19 candidates. What do we know?

5 years ago

Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology ...

5 years ago

UK investigators say a drug reduced Covid-19 deaths for the first time. The world ponders what to do next

5 years ago

Avidity tops up IPO at $298M; Bristol Myers keeps a Celgene discovery pact alive

5 years ago

BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox

5 years ago

First page Previous page 817 818 819820821 822 823 Next page Last page